The Effect of Dolutegravir on Whole-Body Glucose Disposal and Lipid Metabolism in Healthy Volunteers
Background: Dolutegravir (DTG) is a second-generation HIV integrase inhibitor prescribed in combination with other antiretrovirals (ARVs). Although DTG has shown success in achieving and maintaining virological suppression, there is interest in the effects of DTG on glucose disposal and metabolic outcomes including diabetes mellitus. The aim of this study was to assess glucose disposal in…